Insulin Resistance  >>  pioglitazone  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pioglitazone / Generic mfg.
PRISMA, NCT00772174 / 2006-000725-54: Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes

Completed
3
418
Europe
Pioglitazone and Metformin, ACTOS®, AD4833, Metformin
Takeda
Diabetes Mellitus
02/08
02/08
NCT01026194: Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes

Completed
3
204
Japan
Placebo / Teneli (Teneligliptin) + pio (pioglitazone), Teneli / Teneli + pio
Mitsubishi Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
06/11
06/11
PEGLIST C, NCT00927290 / 2008-006225-14: Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance

Terminated
3
40
Europe
Pioglitazone, Placebo
French National Agency for Research on AIDS and Viral Hepatitis
Chronic Hepatitis C, Insulin Resistance
07/12
07/12
NCT00153166: ARREST PAD (Peripheral Arterial Disease)

Completed
2/3
76
US
atorvastatin and pioglitazone, atorvastatin: lipitor, pioglitazone: actos, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo
Brigham and Women's Hospital, National Heart, Lung, and Blood Institute (NHLBI)
Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
11/10
12/11

Download Options